Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16808348 | 0.88 | CA1 (0.55) | CA1CA2SIGMAR1 | |
| SCHEMBL26554581 | 0.88 | THRA (0.50) | ESRRGNPC1RAB9AMLYCD | |
| SCHEMBL966019 | 0.86 | CA1 (0.48) | CA1CA2SIGMAR1 | |
| SCHEMBL23254739 | 0.85 | MCHR1 (0.49) | ESRRGCA1CA2ESRRBDGAT1 | |
| SCHEMBL2329880 | 0.85 | TDP1 (0.54) | ESRRGCA1CA2ESRRBNPC1 | |
| SCHEMBL25943313 | 0.85 | CA1 (0.52) | CA1CA2SIGMAR1 | |
| SCHEMBL30048842 | 0.84 | CA2 (0.59) | CA1CA2SIGMAR1 | |
| SCHEMBL26554575 | 0.84 | L3MBTL1 (0.52) | ESRRGCA1CA2NPC1RAB9A | |
| SCHEMBL18226968 | 0.83 | CA1 (0.48) | ESRRGCA1CA2NPC1RAB9A | |
| SCHEMBL25951448 | 0.82 | CA1 (0.55) | CA1CA2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7820678-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7345044-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060142581-A1 | Hetero substitued sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-7030117-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-7026325-B2 | Sodium channel blockers | PARION-SCIENCES, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20060063780-A1 | Sodium channel blockers | JOHNSON MICHAEL R | 2006-03-23 | — | — | US | disclosed |
| EP-1599096-A4 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-6995160-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1599096-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6903105-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050113389-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113388-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113390-A1 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004073629-A2 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162296-A1 | Sodium channel blockers | PARION SCIENCES, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142581-A1 | Hetero substitued sodium channel blockers | SCN2B, CACNA1B, CACNA1G | ESRRG 2696/4885CA1 2788/4885CA2 329/4885 |
| US-20050113390-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
| US-20050113389-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
| US-20050113388-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
| US-20040162296-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
| US-20060063780-A1 | Sodium channel blockers | HCN4, SCN2B, SCN5A | ESRRG 4429/4885CA1 873/4885CA2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.